-
HEALTH TECHNOLOGY ASSESSMENT RELEVANT VALIDATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN FIRST-LINE METASTATIC TRIPLE-NEGATIVE BREAST CANCER: A BAYESIAN META-ANALYTIC FRAMEWORK
Aug 11, 2026, 17:16 PM -
DEVELOPMENT AND VALIDATION OF THE COMPLICATION MODEL FOR OBESITY AND OVERWEIGHT (COMET): A PATIENT-LEVEL STOCHASTIC MICROSIMULATION MODEL FOR OBESITY-RELATED COMPLICATIONS AND MORTALITY
Aug 11, 2026, 17:16 PM -
BIMEKIZUMAB IMPACT ON PAIN AND QUALITY OF LIFE STRATIFIED BY IHS4 LEVELS IN PATIENTS WITH HIDRADENITIS SUPPURATIVA: 3-YEAR RESULTS FROM BE HEARD EXT
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF TOLVAPTAN IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A STUDY FROM A JORDANIAN PUBLIC PAYER PERSPECTIVE
Aug 11, 2026, 17:16 PM -
COST SAVINGS ASSOCIATED WITH THE INTRODUCTION OF SUBCUTANEOUS VERSUS INTRAVENOUS PEMBROLIZUMAB IN GREECE
Aug 11, 2026, 17:16 PM -
PUBLISHED CLINICAL AND ECONOMIC EVIDENCE AS A PREREQUISITE FOR ASSESSING THE VALUE OF CONTINUOUS GLUCOSE MONITORING SYSTEMS (CGM)
Aug 11, 2026, 17:16 PM -
MOMELOTINIB RESULTS IN COST SAVINGS VS RUXOLITINIB FOR PATIENTS WITH MYELOFIBROSIS AND MODERATE TO SEVERE ANAEMIA
Aug 11, 2026, 17:16 PM -
MANAGEMENT OF POST-SURGICAL PERIPHERAL NEUROPATHIC PAIN IN ADULTS: A FRENCH SURVEY
Aug 11, 2026, 17:16 PM -
XLGEN: A STRUCTURE-FIRST KNOWLEDGE GRAPH FRAMEWORK FOR AI-ASSISTED QUALITY CONTROL OF EXCEL-BASED BUDGET IMPACT MODELS
Aug 11, 2026, 17:16 PM -
FROM REACTIVE TO PREDICTIVE: A HUMAN-IN-THE-LOOP AI FRAMEWORK FOR ANTICIPATORY PICO SCOPING FOR EU JOINT CLINICAL ASSESSMENTS
Aug 11, 2026, 17:16 PM -
ECONOMIC IMPACT OF RECOMBINANT ACTIVATED FACTOR VII PROPHYLAXIS IN SEVERE GLANZMANN THROMBASTHENIA: A PROSPECTIVE COHORT ANALYSIS FROM SAUDI ARABIA
Aug 11, 2026, 17:16 PM -
LEARNING WHILE USING: EVIDENCE EXPECTATIONS UNDER NICE'S REFORMED HEALTHTECH PROGRAM
Aug 11, 2026, 17:16 PM -
CAREGIVER BURDEN OF DISEASE IN A EUROPEAN REAL-WORLD GENERALIZED MYASTHENIA GRAVIS POPULATION AS REPORTED BY PHYSICIANS AND CAREGIVERS
Aug 11, 2026, 17:16 PM -
SYSTEMATIC REVIEW OF THE METHODOLOGY, MODEL STRUCTURE, AND DATA INPUTS OF HEALTH ECONOMIC MODELS EVALUATING SYSTEMIC THERAPIES IN ATOPIC DERMATITIS
Aug 11, 2026, 17:16 PM -
TIME FROM AEMPS AUTHORIZATION TO THE FIRST P&R ASSESSMENT IN 2025 AND LAST AVAILABLE CIPM DECISION IN NEW MEDICINES IN SPAIN
Aug 11, 2026, 17:16 PM -
UTILIZING REAL-WORLD EVIDENCE FROM A LARGE TERTIARY HOSPITAL TO TAILOR BUDGET IMPACT PROJECTIONS FOR NAMD THERAPIES
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN OF INTENSIVE CARE UNIT MANAGEMENT FOR DIABETIC KETOACIDOSIS: A PILOT PROSPECTIVE COST ANALYSIS
Aug 11, 2026, 17:16 PM -
BALANCING AMBITION AND REALITY -THE SHIFTING INTERNATIONAL LANDSCAPE OF PERFORMANCE-BASED MANAGED ENTRY AGREEMENTS
Aug 11, 2026, 17:16 PM -
PHARMACEUTICAL SPENDING CAPS ACROSS EUROPE: AN OVERVIEW OF THE CURRENT NATIONAL POLICIES
Aug 11, 2026, 17:16 PM -
HEALTH LITERACY, SHARED DECISION-MAKING AND REASONS FOR LOW MEDICATION ADHERENCE: INSIGHTS FROM A MIXED-METHODS STUDY IN NORWAY
Aug 11, 2026, 17:16 PM
